相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Florida's Second Chance Act, effective July 1 ahead of the 2026-2027 school year, requires students in grades 9-12 to undergo at least one ECG screening before participating in interscholastic athletics. - A mandatory ECG screening identified an asymptomatic atrial septal defect in sophomore athlete Cameron Crider, who is scheduled for surgery in October and expected to return to sports next season. - Experts note that up to 80% of young athletes who suffer sudden cardiac arrest have no warning symptoms, and an ECG can detect about 80% of at-risk conditions versus 80-90% missed by standard sports physicals alone. - Critics warn that universal EKG screening can produce false-positive results in up to 15% of healthy adolescents, leading to costly follow-up testing and exclusion from sports, and the American Heart Association does not recommend mandatory screening for all student athletes.
- A new study published in Nature Cancer reveals that the neurotransmitter GABA selectively fuels glioblastoma growth in females by reprogramming granulocytic MDSCs through the L-Arg–NOS2 pathway. - Blocking GABA receptor B (GABBR) signaling with the antagonist CGP 35348 significantly extended survival in female mouse models of glioblastoma but had no effect in males. - Human tumor biopsies confirmed that female glioblastoma patients have higher GABA levels and GABBR expression in tumor-infiltrating immune cells compared to male patients. - The findings open the door to sex-specific immunotherapies targeting GABA signaling, with potential applications beyond glioblastoma to other cancers where MDSCs play a role.
- A new clinical trial at the University of Miami is evaluating whether a single infusion of mesenchymal stem cells combined with anti-amyloid therapy can stabilize cognitive decline in early Alzheimer's disease. - The study builds on a prior Phase I trial of Lomecel-B that showed no serious adverse events and suggested cognitive stabilization at lower doses with favorable biomarker changes. - The dual-target approach addresses both amyloid accumulation and neuroinflammation, leveraging the immunomodulatory and regenerative properties of mesenchymal stem cells. - The global stem cell therapy market for neurological disorders was valued at USD 2.38 billion in 2025 and is projected to reach USD 12.67 billion by 2035, growing at a CAGR of 17.90%.
- Sylvester Comprehensive Cancer Center has launched a phase I clinical trial combining oncolytic virus SVV-001 with checkpoint inhibitors nivolumab and ipilimumab for high-grade neuroendocrine tumors. - The trial has completed its first three dose levels with no severe treatment-related side effects reported, targeting patients whose tumors have become resistant to previous therapies. - Researchers identified tumor endothelial marker 8 (TEM8) as a biomarker expressed only on cancer cells, which SVV-001 specifically targets to enhance immune recognition. - High-grade neuroendocrine cancer affects about one-sixth of neuroendocrine tumor patients, with most succumbing within one to two years due to limited treatment options beyond conventional chemotherapy.
- PolarityBio completed its COVER DFUS II Phase III trial for SkinTE, an autologous skin multicellular therapy for Wagner 1 diabetic foot ulcers, with the last patient visit occurring on November 12, 2025. - The registrational study enrolled 120 patients across multiple U.S. sites in 14 months and is designed to support a Biologics License Application for what could be the first BLA-approved therapy in chronic wound indication since 1997. - SkinTE received FDA Breakthrough Therapy designation earlier this year, highlighting its potential to substantially improve treatment for diabetic foot ulcers that affect millions of patients worldwide. - Final trial results are anticipated in the first quarter of 2026, with the primary endpoint measuring complete wound closure within 12 weeks compared to standard of care alone.
- Researchers at Sylvester Comprehensive Cancer Center developed a novel protocol using TL1A-Ig fusion protein and low-dose IL-2 to expand regulatory T cells before stem cell transplant, demonstrating improved survival rates and reduced GVHD severity in preclinical studies. - The therapy works by stimulating the patient's own immune system to create a safer transplant environment while maintaining graft-versus-leukemia activity, offering an alternative to broad immune suppression. - Preclinical results showed higher survival rates, better tissue integrity, and a more diverse gut microbiome, with the protocol working entirely in vivo to expand Tregs in key organs like the colon, liver, and eyes. - The approach could simplify treatment and make stem cell transplants more accessible by eliminating the need to manipulate donor cells outside the body, with clinical trials being planned.
- Xenon Pharmaceuticals will present seven posters at AES 2025, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures. - The presentations will feature ≥48-month interim analysis data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. - Additional data will highlight the impact of depression on epilepsy patients and new pre-clinical findings from the company's early-stage NaV1.1 program in Dravet syndrome. - Xenon will also host a symposium with the Epilepsy Foundation of America exploring depression and anxiety in epilepsy, featuring leading epileptologists from major medical centers.
- Erdafitinib demonstrated a predictable safety profile with 8 mg daily identified as the recommended phase 2 dose in patients with recurrent IDH wild-type glioma harboring FGFR-TACC gene fusions. - Preliminary efficacy data from 5 patients showed encouraging responses including one complete response, two partial responses, and one stable disease case. - The study represents the first clinical trial focused specifically on examining erdafitinib activity in gliomas with F3T3 fusions, targeting a genetic alteration present in 3-6% of adult IDH wild-type gliomas. - Two detailed case studies demonstrated durable responses, with one patient achieving complete response at cycle 13 and another showing partial response at cycle 8.
- Researchers identified three genetic mutations in the CPD gene that cause congenital sensorineural hearing loss in families from Turkey, affecting the production of arginine and nitric oxide signaling. - Laboratory studies demonstrated that sildenafil (Viagra) and L-arginine supplementation can restore nitric oxide levels and reduce hair cell death in the inner ear. - The findings suggest a potential therapeutic pathway for treating this rare form of genetic deafness, though experts caution against using Viagra for hearing issues without further human trials.
- The ALTUS study, the largest prospective trial of a blood test for liver cancer surveillance in the U.S., demonstrated that Oncoguard Liver detected three times more early-stage hepatocellular carcinomas than ultrasound (67% vs 22%). - The blood test achieved seven times greater sensitivity for very early-stage liver cancer compared to standard ultrasound (64% vs 9%), with 82% specificity exceeding clinical utility benchmarks. - Results address critical gaps in liver cancer screening, where fewer than 30% of eligible patients participate in regular surveillance despite liver cancer being among the fastest-growing causes of cancer deaths in the United States.
